Internal correspondence from the sugar industry. Paid Harvard scientists. Buried clinical data. A documented account of how American dietary guidelines became the leading driver of metabolic disease — and what the world's longest-lived people have been doing instead.
For most of the 20th century, type 2 diabetes was a rare disease. In 1960, it affected roughly one in every hundred Americans. By 2024, that figure had climbed to more than one in nine. The annual cost to American patients, employers, and insurers now exceeds $412 billion.
The standard explanation — that we eat too much, exercise too little, and inherited the wrong genes — is partially true, but it omits the more uncomfortable part of the story. A series of documents recovered from university archives, peer-reviewed papers published as recently as 2016, and longitudinal data from three indigenous populations point at a more specific origin: a coordinated industry campaign, beginning in the mid-1960s, that misdirected American dietary science for fifty years.
What follows is an account of that campaign, its measurable consequences, and the parallel research — long ignored by mainstream nutrition — pointing at a specific cellular mechanism behind the modern blood sugar crisis. It is also an account of what the world's longest-lived population appears to have been doing right all along.
In the spring of 1965, an executive named John Hickson — at the time, vice president of a trade group called the Sugar Research Foundation — circulated an internal memo proposing what he called "a major program" to counter what he described as "negative attitudes toward sugar." Heart disease rates were climbing. Diabetes diagnoses were creeping upward. A growing body of research was pointing at refined sugar as a likely contributor, and the industry needed, in Hickson's words, to "publish our data and refute our detractors."
By late 1965, the Sugar Research Foundation had finalized an agreement with three researchers at the Harvard School of Public Health. The lead investigator was a nutrition scientist named D. Mark Hegsted. The Foundation paid the group the modern equivalent of approximately $48,900 to $50,000 to produce a literature review that would, in the Foundation's framing, "set the record straight."
The resulting paper was published in 1967 in the New England Journal of Medicine. It concluded that reducing dietary fat — not sugar — was the only intervention needed to prevent heart disease. It used, by the later assessment of independent reviewers, a clear double standard: studies implicating sugar were dismissed for methodological flaws; studies blaming fat with identical flaws were accepted without comment. The sugar industry's funding was not disclosed.
Mark Hegsted would go on, a decade later, to become head of nutrition at the U.S. Department of Agriculture, where he played a direct role in developing what would become the federal dietary guidelines. Those guidelines became the foundation for the 1980 food pyramid, which placed refined grains at its base and instructed the American public to eat 6 to 11 servings of them per day, while sharply restricting fat.
The documents establishing this chain of events sat unread in basement archives for nearly five decades. They were recovered in the 2010s by a researcher named Cristin Kearns at the University of California, San Francisco. Her analysis appeared in JAMA Internal Medicine in September 2016.
The clinical consequences of the 1977 dietary guidelines and the 1980 food pyramid took roughly a decade to become visible in national health data, but once they did, the curve was unmistakable. The food industry — given a regulatory green light to reduce fat in packaged products — reformulated thousands of staple foods. The replacement for fat, in nearly every case, was sugar.
What followed was the most rapid expansion of a chronic disease in American history.
Global figures followed a similar trajectory. The World Health Organization estimates that 422 million adults were living with diabetes worldwide in 2014, more than double the 1980 figure. Forecasts project that number reaching 783 million by 2045.
The annual cost to Americans alone — counting medication, hospitalizations, lost productivity, and complications — reached $412.9 billion in 2022. The global diabetes drug market, valued at $66 billion in 2023, is projected to reach $132 billion by 2034. A single month's supply of one common GLP-1 medication retails in the United States for nearly nine hundred dollars; the same drug costs $59 in Germany.
The standard explanation for this curve — that Americans ate more, exercised less, and got older — accounts for some of it. But it does not explain why diabetes prevalence increased far faster than caloric intake or obesity rates. It does not explain why the rise tracks almost perfectly with the implementation of low-fat, high-grain dietary guidelines. And it does not explain why a small number of populations, eating completely different diets, saw none of it.
Of all the data sets relevant to this story, perhaps none is more clarifying than what nutrition researchers refer to, somewhat informally, as the Pima Paradox.
The Pima are an indigenous people whose ancestral lands span what is now southern Arizona and northwestern Mexico. Several centuries ago, a portion of the population migrated south. Their descendants today live in the Sierra Madre Mountains of Sonora, Mexico. Genetic typing has confirmed that the Arizona and Mexican Pima populations are essentially identical at the DNA level.
The Arizona Pima have, by a substantial margin, the highest recorded type 2 diabetes rate of any population on Earth: roughly 38% of adults are diabetic. The first documented case of diabetes in the Arizona Pima appears in medical records in 1902 — that is, after the introduction of Western foods to the reservation.
The Mexican Pima, who continued subsistence farming a traditional diet of beans, squash, corn, and small amounts of meat, have a type 2 diabetes rate of 6.9%.
The Pima are not the only such case. Aboriginal Australian populations, when documented on traditional diets, showed no evidence of diabetes, heart disease, or obesity. On contemporary Western diets, current diabetes prevalence in some Aboriginal communities exceeds 42%. In a widely cited 1984 study, a group of Aboriginal Australian volunteers returned to their traditional diet and lifestyle for seven weeks; researchers reported that their metabolic markers showed near-complete reversal of their diabetes.
Pacific Islander populations show the same pattern. Diabetes was, until the mid-20th century, virtually nonexistent on the traditional Pacific Islander diet. Today, American Samoa records the highest national diabetes prevalence on Earth. The change tracks the introduction of Western processed foods after the Second World War.
None of these populations changed genetically in the relevant time period. What changed was the food.
If the Pima Paradox demonstrates what the modern Western diet does to a healthy population, the Okinawa data set demonstrates something approximately opposite. Okinawa is a small Japanese island chain in the East China Sea. On their traditional diet, Okinawans were among the longest-lived people ever recorded, with an average life expectancy exceeding 84 years, rates of coronary heart disease roughly one-eighth that of the United States, and, by reliable accounts, virtually no type 2 diabetes.
The Okinawan diet differs from the Pacific Islander and Aboriginal Australian traditional diets in nearly every detail except one. All four diets are heavy in marine sources — fish, shellfish, and seaweed. All four contain unusually high concentrations of a class of compounds called marine carotenoids.
The most studied of these is a compound called astaxanthin. It is the pigment that gives wild salmon their pink color. It is concentrated in shrimp, krill, and the microalgae they feed on. And it is present in the diet of every traditional population, worldwide, that has shown unusually low rates of metabolic disease.
The Okinawan principle of nuchi gusui, often translated as "food is medicine," predates the modern understanding of carotenoid biology by several centuries. The translation appears to be more precise than expected.
To understand why a marine compound concentrated in salmon and shrimp would have anything to do with blood sugar, it helps to step back from the current model of diabetes and look at the upstream biology.
Insulin works by binding to receptors on the surface of cell membranes. When the receptors are healthy, insulin docks, the cell opens its glucose channels, and blood sugar enters where it can be used for energy. When the receptors are damaged, this process breaks down. Glucose accumulates in the bloodstream. The pancreas produces more insulin to compensate. The damaged receptors remain damaged. This is the cellular signature of insulin resistance, and it is the upstream cause of nearly every case of type 2 diabetes.
What damages the receptors? A growing body of research points at a process called oxidative stress — the cellular wear caused by reactive molecules called free radicals. The modern Western diet, with its industrial seed oils, processed carbohydrates, and steady glucose spikes, produces free radicals at rates the human body did not evolve to handle. Over years, these free radicals oxidize the lipid membranes of cells, including the membranes where insulin receptors live.
This is the cellular damage that diabetes medications do not address. Metformin slows glucose production in the liver. Berberine works on a similar pathway. GLP-1 medications slow gastric emptying. None of them repair the underlying receptor damage. They manage the symptom while the upstream injury continues.
The reason astaxanthin draws specific research attention is structural. Of every known dietary antioxidant, astaxanthin is essentially the only one whose molecular geometry allows it to position itself across both the inner and outer surface of a cell membrane simultaneously. Vitamin C is water-soluble and protects only the outside of the membrane. Vitamin E is fat-soluble and protects only the inside. Berberine works in the liver. Astaxanthin sits inside the membrane structure itself — protecting the receptor from oxidative damage on both faces at once.
This explains, mechanically, why the antioxidant supplements most patients have already tried do not produce meaningful HbA1c improvement. They are not targeting the wrong philosophy. They are using compounds that physically cannot reach the location of the damage.
In 2021, a research group led by Dr. M. Urakaze published a clinical trial in the peer-reviewed journal Diabetes, Obesity and Metabolism. The trial was, in the authors' own framing, "the first report showing that daily oral administration of 12mg astaxanthin significantly reduces HbA1c levels in humans."
The protocol was straightforward. Participants with elevated HbA1c took 12mg of natural astaxanthin daily for twelve weeks. Researchers measured glycated hemoglobin and several other metabolic markers before, during, and after the trial. They also tracked adverse events.
The HbA1c reductions reached statistical significance. Just as notably, the side effect profile contained almost nothing of clinical significance. The authors reported the supplement as "well tolerated with no clinically apparent side effects."
For context, the comparable figure for metformin is that roughly 30% of users experience gastrointestinal side effects severe enough to disrupt daily life. For berberine, independent trial data places the figure at 34.5%. The astaxanthin trial reported essentially none.
A second trial, led by Dr. Theodore P. Ciaraldi at the University of California San Diego and published in 2023, extended the findings into patients with prediabetes and dyslipidemia. The astaxanthin group showed reductions in cholesterol and cardiovascular risk markers — again, with no significant side effects.
These results are not a cure, and the authors do not present them as one. Astaxanthin is a dietary supplement, not a pharmaceutical drug. But the data does suggest that, for the first time in the modern era of blood sugar management, there exists a clinically studied compound that targets the upstream cellular damage rather than the downstream glucose number — and does so without the quality-of-life cost that has driven so many patients to abandon their other treatments.
It is rare to encounter a piece of nutrition research where the experimental timeline aligns precisely with the patient's own monitoring schedule, but in this case it does. The 2021 trial used a twelve-week protocol. The 2023 follow-up used a similar window. American physicians typically order HbA1c tests every ninety days.
This means, for the first time, that a person reading an article like this one has access to an objective measurement system that confirms or refutes what the published research suggests — on a timeline they did not have to design themselves. The next blood draw will say what it says.
The decision in front of any individual patient is straightforward. It is also entirely their own. A patient currently taking metformin, insulin, or any other prescribed medication should not change their regimen without direct supervision from a qualified physician. Astaxanthin is studied as a complementary support, not as a replacement.
But the question of whether to add cellular repair to whatever protocol is currently in place — that is a question the next blood draw is, in a real sense, already being shaped by.
Natural astaxanthin sourced from Haematococcus pluvialis microalgae, suspended in MCT oil for absorption, manufactured in a GMP-certified U.S. facility, third-party batch tested, and backed by a 90-day money-back guarantee — one full HbA1c testing cycle.
See the Astaxanthin 12mg FormulaDisclaimer: The information presented in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Always consult your healthcare provider before starting any new supplement, particularly if you are pregnant, nursing, taking medication, or have a medical condition. Individual results may vary. This article references historical events and peer-reviewed research; it does not assert causation beyond what those sources support.